June 16th, 2022
Research Nester released a report titled “Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment Market: Global Demand Analysis & Opportunity Outlook 2030″ which delivers detailed overview of the global relapsing-remitting multiple sclerosis (RRMS) treatment market in terms of market segmentation by drug type, route of administration, end-user and region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
The relapsing-remitting multiple sclerosis (RRMS) treatment market is projected to grow with a moderate CAGR during the forecast period, i.e., 2022-2030, on account of the increasing prevalence of multiple sclerosis globally. According to the National Multiple Sclerosis Society (NMSS), relapsing-remitting multiple sclerosis (RRMS) is the most common type of multiple sclerosis, accounting for nearly 85% of the diagnosis. In addition to this, the development of the latest formulations to provide effective treatment is also a key factor fueling the market’s growth.
The global relapsing-remitting multiple sclerosis (RRMS) treatment market is divided by drug type into beta-interferon, cladribine, dimethyl fumarate, fingolimod, ozanimod, and others, out of these, the beta interferon segment is projected to capture a larger share of the market during the forecast period, on account of its high efficacy. Additionally, over the past decade, beta-interferon therapy has been the first-line treatment of relapsing-remitting multiple sclerosis.
Get a PDF Sample for more detailed market insights:-https://www.researchnester.com/sample-request-3133
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The market in the North America region currently captures the larger share of the market, which is primarily attributed to the region’s efficient healthcare infrastructure. Additionally, the growing prevalence of multiple sclerosis in the United States and Canada is also contributing to the growth of the market in the region. According to the Multiple Sclerosis Association of America, nearly 1 million people in the United States are affected by the disease. Along with this, the region’s growing geriatric population, with over 54 million people above 65 years of age, is also anticipated to drive the growth of the market in the forthcoming years.
Growing Prevalence of Multiple Sclerosis to Drive Market Growth
According to the National Institute of Health (NIH), the estimated number of people living with multiple sclerosis globally has increased to approximately 2.8 million in 2020.
As the prevalence of the disease increases, the treatment landscape of the disease is also evolving, which, in turn, is anticipated to create lucrative opportunities for the market in the upcoming years.
However, high cost of treatment is estimated to act as a restraint in market growth.
This report also provides the existing competitive scenario of some of the key players of the global relapsing-remitting multiple sclerosis (RRMS) treatment market which includes company profiling of Biogen Inc., Eisai Co., Ltd., Glenmark Pharmaceuticals, Merck KGaA, Novartis AG, Sanofi-aventis Groupe, Teva Pharmaceutical Industries Ltd., Genentech, Inc., Acorda Therapeutics, Inc. and Amneal Pharmaceuticals LLC.
Access Full Report, here:-https://www.researchnester.com/sample-request-3133
The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global relapsing-remitting multiple sclerosis (RRMS) treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Add dv554822 to your subscriptions feeddv554822